Abstract
Historically, antiestrogen is the first targeted therapy used in breast cancer treatment. In fact, its rationale lies in the molecular pathways elucidated by basic research. In estrogen receptor (ER)-alpha positive metastatic breast cancer patients, hormone-therapy remains the first option of treatment. While tamoxifen concomitant with suppression of ovarian function with luteinizing hormone releasing hormone (LHRH) agonists is the standard first line treatment in premenopausal, third generation aromatase inhibitors (AIs) are the first line standard hormone therapy in postmenopausal. However, the development of acquired resistance during antiestrogen therapy continues to be a central clinical problem. This review provides an update on the antiestrogen action and report on immunological treatment of the advanced disease by some cytokines. Interleukin-2, interleukin-12 and interferons used alone or in combination demonstrated an anti-tumor action directly and/or through synergism with antiestrogens. A rationale for the addition of interferon-beta and interleukin-2 to antiestrogens is described. Furthermore, we summarize and interpret the clinical and laboratory data of a recent long-term hormone- immunotherapy study in metastatic endocrine dependent breast cancer patients. Prospective randomized trials are necessary to confirm some recent promising results based on an immunological approach in addition to antiestrogens to overcome or delay acquired hormone resistance.
Keywords: Breast cancer, cytokines, distant metastases, hormone therapy, immunotherapy.
Current Drug Targets
Title:Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update
Volume: 17 Issue: 10
Author(s): Andrea Nicolini, Angelo Carpi, Paola Ferrari, Pier Mario Biava and Giuseppe Rossi
Affiliation:
Keywords: Breast cancer, cytokines, distant metastases, hormone therapy, immunotherapy.
Abstract: Historically, antiestrogen is the first targeted therapy used in breast cancer treatment. In fact, its rationale lies in the molecular pathways elucidated by basic research. In estrogen receptor (ER)-alpha positive metastatic breast cancer patients, hormone-therapy remains the first option of treatment. While tamoxifen concomitant with suppression of ovarian function with luteinizing hormone releasing hormone (LHRH) agonists is the standard first line treatment in premenopausal, third generation aromatase inhibitors (AIs) are the first line standard hormone therapy in postmenopausal. However, the development of acquired resistance during antiestrogen therapy continues to be a central clinical problem. This review provides an update on the antiestrogen action and report on immunological treatment of the advanced disease by some cytokines. Interleukin-2, interleukin-12 and interferons used alone or in combination demonstrated an anti-tumor action directly and/or through synergism with antiestrogens. A rationale for the addition of interferon-beta and interleukin-2 to antiestrogens is described. Furthermore, we summarize and interpret the clinical and laboratory data of a recent long-term hormone- immunotherapy study in metastatic endocrine dependent breast cancer patients. Prospective randomized trials are necessary to confirm some recent promising results based on an immunological approach in addition to antiestrogens to overcome or delay acquired hormone resistance.
Export Options
About this article
Cite this article as:
Nicolini Andrea, Carpi Angelo, Ferrari Paola, Biava Mario Pier and Rossi Giuseppe, Immunotherapy and Hormone-therapy in Metastatic Breast Cancer: A Review and an Update, Current Drug Targets 2016; 17 (10) . https://dx.doi.org/10.2174/1389450117666160201114752
DOI https://dx.doi.org/10.2174/1389450117666160201114752 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response, and/or therapy ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial (Thematic Issue: Antiangiogenic Agents in the Management of Solid Malignancies)
Current Angiogenesis (Discontinued) Toll-Like Receptor (TLR) Response Tolerance: A Key Physiological “ Damage Limitation ” Effect and an Important Potential Opportunity for Therapy
Current Medicinal Chemistry Truncated Human Cathepsin L, Encoded by a Novel Splice Variant, Exhibits Altered Subcellular Localization and Cytotoxicity
Protein & Peptide Letters Persistent P21Cip1 Induction Mediates G1 Cell Cycle Arrest by Methylseleninic Acid in DU145 Prostate Cancer Cells
Current Cancer Drug Targets Cytochrome P450-Activated Prodrugs: Targeted Drug Delivery
Current Medicinal Chemistry Advancements in the Understanding of Paclitaxel Metabolism in Tissue Culture
Current Pharmaceutical Biotechnology Current Progress and Perspectives of CDC20 in Female Reproductive Cancers
Current Molecular Medicine Synthesis and Characterization of Quinoline-3-Carboxamide Derivatives as Inhibitors of the ATM Kinase
Current Topics in Medicinal Chemistry Prevention of Colitis-associated Cancer: Natural Compounds that Target the IL-6 Soluble Receptor
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Targets for Metastatic Prostate Cancer
Current Drug Targets Diffusion-Weighted Magnetic Resonance Imaging in Pelvic Cancer
Current Medical Imaging Association between hTERT Polymorphisms and Female Papillary Thyroid Carcinoma
Recent Patents on Anti-Cancer Drug Discovery The Sentinel Node and Occult Lesion Localization (SNOLL) Technique Using a Single Radiopharmaceutical in Non-palpable Breast Lesions
Current Medical Imaging Superparamagnetic Iron Oxide Nanoparticles (SPIONs) for Diagnosis and Treatment of Breast, Ovarian and Cervical Cancers
Current Drug Metabolism From Multiple PAR1 Receptor/Protein Interactions to their Multiple Therapeutic Implications
Current Topics in Medicinal Chemistry Estrogen Catechols Detection as Biomarkers in Schistosomiasis Induced Cancer and Infertility
Letters in Drug Design & Discovery Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Identification of Novel Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma using Bioinformatics Analysis
Combinatorial Chemistry & High Throughput Screening The Clinical Translation of Organic Nanomaterials for Cancer Therapy: A Focus on Polymeric Nanoparticles, Micelles, Liposomes and Exosomes
Current Medicinal Chemistry Characterization of Solid Lipid Nanoparticles Containing Caffeic Acid and Determination of its Effects on MCF-7 Cells
Recent Patents on Anti-Cancer Drug Discovery